Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Effects of PA-1 Transcriptional Regulation on Monocyte Function

This study has been terminated.
(Investigator left institution)
National Institutes of Health (NIH)
Information provided by:
Vanderbilt University Identifier:
First received: August 3, 2007
Last updated: July 14, 2011
Last verified: July 2011
Researching genetic differences in people with no prior medical conditions for better understanding of cardiac diseases through genetic research.


Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Angiotensin, the Vascular Endothelium, and Fibrinolysis - The Effects of PAI-1 Transcriptional Regulation on Human Monocyte Function

Resource links provided by NLM:

Further study details as provided by Vanderbilt University:

Estimated Enrollment: 125
Study Start Date: March 2006
Study Completion Date: July 2011
Detailed Description:
The discovery and subsequent application of small interfering RNA (siRNA) methods to achieve individual gene silencing in mammalian cells is a robust method that is well-described and validated in mammalian cell culture systems. We will apply this technique to achieve post-transcriptional "silencing" of PAI-1 in monocytes obtained from otherwise healthy volunteers, and study the subsequent loss of this gene's function on the migratory capacity of these cells in the proposed in vitro experimental system. This concept has not yet been demonstrated in the literature, and if validated, would be a novel and fundamental description of the role of PAI-1 in human monocyte biology as related to the development of atherosclerosis.

Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Obese men and women

Inclusion Criteria:

  • Ages 18 -50
  • No current or past medical problems

Exclusion Criteria:

  • Patients taking prescription drugs (hormonal birth control or herbal supplements may be taken.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00512369

United States, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232
Sponsors and Collaborators
Vanderbilt University
National Institutes of Health (NIH)
Principal Investigator: Mohan Sathyamoorthy, MD Vanderbilt University
  More Information

Responsible Party: Douglas Vaughan, Vanderbilt University Identifier: NCT00512369     History of Changes
Other Study ID Numbers: 060286  NIH 
Study First Received: August 3, 2007
Last Updated: July 14, 2011
Health Authority: United States: Institutional Review Board
United States: Food and Drug Administration

Keywords provided by Vanderbilt University:
Metabolic pathways
Monocyte Function

Additional relevant MeSH terms:
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases processed this record on October 21, 2016